Paulette announced that the controlling shareholder is planning a change of control. Due to uncertainties, trading of the company's shares and “Polaray Bonds Convertible” will be suspended from the opening of the market on August 3, 2026, and “Polaroid Bonds Transfer” will be suspended. The “Paulette Blood Purification Industrial Base and R&D Center Project” has been completed, part of the “Marketing Network and Information Technology Construction Project” is to be completed and partially terminated. The remaining capital raised is RMB 606.631 million to permanently supplement working capital. CSIC Pengyuan maintained the credit rating of the company's principal and “Polaroid Convertible Bonds” at AA -, and the rating outlook was negative.

Paulette announced that the controlling shareholder is planning a change of control. Due to uncertainties, trading of the company's shares and “Polaray Bonds Convertible” will be suspended from the opening of the market on August 3, 2026, and “Polaroid Bonds Transfer” will be suspended. The “Paulette Blood Purification Industrial Base and R&D Center Project” has been completed, part of the “Marketing Network and Information Technology Construction Project” is to be completed and partially terminated. The remaining capital raised is RMB 606.631 million to permanently supplement working capital. CSIC Pengyuan maintained the credit rating of the company's principal and “Polaroid Convertible Bonds” at AA -, and the rating outlook was negative.